Kurser indlæses...
Prognose
| Køb |
4 |
| Behold |
4 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Acer pauses release of oversized Nitro Blaze 11 handheld amid tariffs and manufacturing shifts
Acer’s 11‑inch Nitro Blaze gaming handheld, unveiled at CES 2025 with a planned Q2 release, has been delayed indefinitely. Company says US tariffs forced it to prioritize core laptop lines and seek manufacturing outside China, leaving the Blaze and smaller siblings without imminent launch plans. Acer confirms the devices are on the back burner with no current timeline for release. » Mere på theverge.com
Acer unveils Swift 16 AI with world’s largest haptic trackpad and stylus
Acer introduced refreshed Swift, Nitro and Predator laptops at CES 2026, led by the Swift 16 AI featuring a 175.5 x 109.7 mm haptic trackpad and included stylus, optional OLED and Intel Panther Lake chips up to Core Ultra X9 388H. Other updates include Swift Go and Swift Edge models with Panther Lake chips (Swift Go 16 AI to use AMD) and contextual media controls on mechanical trackpads. Gaming lineup adds Nitro V 16S AI and Predator Helios Neo 16S AI with Nvidia RTX 50-series GPUs and Panther Lake CPUs. Acer gave release windows but no pricing: Swift 16 AI and Swift Go 16 AI expected in Q1 2026, other Swifts in Q2, and the gaming models in Q3. » Mere på theverge.com
Acer unveils multiple laptops and monitors ahead of IFA 2025 in Berlin
Ahead of IFA 2025 in Berlin, Acer announced a wide range of new products including the Chromebook Plus Spin 514 with MediaTek Kompanio Ultra 910, the ultra-light Swift Air 16, refreshed Predator gaming laptops and several stylish monitors including Amadana-branded models. Coverage also highlights other IFA product reveals across the show such as LG’s smart-home AI ambitions, JBL’s PartyBox 720 speaker, Dolby Vision 2 updates, Ooni’s AI pizza oven and teaser products from Dangbei. The Verge will provide live coverage and hands-on impressions from the IFA show floor between September 5–9, 2025. » Mere på theverge.com
Virksomhedstal
| (EUR) | 2022 | YoY |
|---|---|---|
| Omsætning | 0 | 100,00 % |
| Bruttofortjeneste | 0 | 100,00 % |
| Nettoresultat | -24,46 mio. | 80,92 % |
| EBITDA | -24,3 mio. | 74,07 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 0 € |
Højeste/laveste i 52 uger | 4,06 € - 0,49 € |
| Udbytte | Nej |
Beta | 0,44 |
P/E (PE Ratio) | -0,37 |
PEG (PEG Ratio) | 0,01 |
K/I (PB Ratio) | -0,62 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Acer Therapeutics Inc., et farmaceutisk selskab, fokuserer på erhvervelse, udvikling og kommercialisering af behandlinger mod alvorlige sjældne og livstruende sygdomme. Selskabets pipeline omfatter fire kandidater i klinisk fase: EDSIVO til behandling af vaskulært Ehlers-Danlos syndrom hos patienter med en bekræftet mutation i type III-kollagen; ACER-001, en formulering af natriumphenylbutyrat til behandling af forskellige medfødte stofskiftesygdomme, herunder ureacyklusforstyrrelser og ahornsirupsygdom; ACER-801 (osanetant) til behandling af inducerede vasomotoriske symptomer; og ACER-2820 (emetin), en værtsrettet behandling mod en række infektionssygdomme, herunder COVID-19. Selskabet har en forskningssamarbejdsaftale med National Center for Advancing Translational Sciences (NCATS) om at udvikle emetinhydrochlorid som en potentiel behandling af patienter med COVID-19; og en licensaftale med Sanofi om at erhverve globale rettigheder til osanetant, en selektiv, ikke-peptid tachykinin NK3-receptorantagonist i klinisk fase. Acer Therapeutics Inc. blev stiftet i 1991 og har hovedkontor i Newton, Massachusetts.
| Navn | Acer Therapeutics |
| CEO | Christopher Schelling |
| Hjemsted | Newton,
ma USA |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 14.04.2004 |
| Medarbejdere | 30 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ACER |
